| Literature DB >> 1602806 |
R Foa1, G Meloni, A Guarini, M Vignetti, D Marchis, S Tosti, A G Tos, F Vischia, F Mandelli, F Gavosto.
Abstract
In this paper we review some of the preclinical findings which have led us to believe that immunotherapy with interleukin 2 (IL2)/lymphokine activated killer (LAK) cells may be a feasible approach in the management of acute myeloid leukemia. The main clinical and biological results so far obtained with IL2 treatment, and the currently ongoing protocols and strategies are discussed.Entities:
Mesh：
Substances：
Year: 1992 PMID： 1602806
Source DB: PubMed Journal: Leukemia ISSN： 0887-6924 Impact factor: 11.528